An interventional study of Test formula and Control formula in Atopic Dermatitis (AD), sponsored by Société des Produits Nestlé (SPN). Recruiting at 25 sites in 5 countries. Open to participants aged 1 Day to 14 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-30.
Sponsored by Société des Produits Nestlé (SPN) (part of Nestlé S.A.) · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies in Dermatitis, Atopic with a site in Spain — 10 open to participants now, 30 under way, 12 of them phase 3. Dermatitis, Atopic · Spain.
Among the 113 studies in Dermatitis, Atopic with a site in Spain, this one is the 43rd largest by planned enrollment of the 104 interventional ones that give a count, is one of 10 that started in 2025, is one of 12 with no phase, reaches primary completion later than 16 of the 29 other live ones, and was the 103rd registered.
1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.
Browse Dermatitis, Atopic studies →10 of the 113 studies in Dermatitis, Atopic with a site in Spain are open now. Recruiting first, the newest first:
Apollo Therapeutics Ltd · Sites in Spain, United States, Bulgaria and 5 more countries
Ages 18–65
Pfizer · Sites in Spain, United States, China and 4 more countries
Ages 2–11
Sanofi · Sites in Spain, United States, Canada and 6 more countries
Ages 12+
Novartis Pharmaceuticals · Sites in Spain, United States, Argentina and 14 more countries
Ages 18–100
Apogee Therapeutics, Inc. · Sites in Spain, United States, Canada and 6 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 1 Day to 14 Days · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 31 · Phase 3 53 · Phase 4 6
First in 1998; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 82 across 1,249 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 306 across the 104 interventional studies, 978 across the 8 observational. Of the 78 that completed or were terminated, 50 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
106 of 113 have an industry lead sponsor. The 10 most frequent:
This study is registered under Société des Produits Nestlé (SPN), one of the names counted as Nestlé S.A.. Under that name alone:
Société des Produits Nestlé (SPN) is the lead sponsor of 324 studies on the registry; 16 are open to participants now.
Nestlé S.A. has 5 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
8 of the studies in Dermatitis, Atopic with a site in Spain that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT06526182Phase 3Almirall, S.A.A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis | 2027-04-25 |
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT06395948Apogee Therapeutics, Inc.A Study Evaluating APG777 in Atopic Dermatitis | 2026-11 |
| NCT07105488Bluefin Biomedicine, Inc.A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis | 2027-02-28 |
Add all 8 to your calendar (.ics) → With an account.
Among the 113 studies in Dermatitis, Atopic with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to assess the efficacy of a partially hydrolyzed formula with synbiotics in halting one of the first steps of the allergic march (atopic dermatitis) in infants at risk of allergy. Other efficacy and safety parameters will be assessed as well.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
a. For the breastfed reference group only: infant is exclusively breastfed since birth with no intake of formula, and their parent(s) have the intention to continue exclusive breastfeeding until at least 4 months of age.
or b. For the randomized formula-fed groups only: infant is exclusively or predominantly formula-fed in the 24 hours prior to enrollment, with formula feeding representing at least 75% of total daily feeds. The decision to introduce formula feeding was independently made by the parents before enrollment.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Partially hydrolyzed formula with synbiotics
Other: Test formula
Intact protein formula without synbiotics
Other: Control formula
Breastfed arm (not applicable for France)
Partially hydrolyzed formula with synbiotics
Intact protein formula without synbiotics
TransEpidermal Water Loss (TEWL) at 3 months
TransEpidermal water loss will be measured using a validated non-invasive technique.
Time frame: At 3 months of age
Cumulative incidence of Atopic Dermatitis
Cumulative incidence of AD is based on physician diagnosis using the United Kingdom Working Party (UKWP) diagnosis criteria.
Time frame: From enrollment to 12 months of age
TransEpidermal Water Loss
Epidermal water loss will be measured using a validated non-invasive technique.
Time frame: From enrollment to 12 months of age
Skin surface (stratum corneum) hydration
Skin hydration will be measured with a corneometer device.
Time frame: From enrollment to 12 months of age
Extent and severity of Atopic Dermatitis
SCORAD (SCORing for Atopic Dermatitis), scores range from 0 to 103, with higher scores indicating higher atopic dermatitis severity
Time frame: From 3 months to 12 months of age
Cumulative use of topical steroids and calcineurin inhibitors
Use of medication to treat AD and other symptoms will be collected via parent self-reported questionnaire.
Time frame: From enrollment to 12 months of age
Skin cytokines
Concentration of skin cytokines such as IL4 and IL5 using immunoassays
Time frame: From enrollment to 12 months of age
Skin natural moisturizing factors
Concentration of skin natural moisturizing factors such as Pyrrolidone carboxylic acid, using HPLC
Time frame: From enrollment to 12 months of age
Skin stratum corneum lipids
Concentration of skin stratum corneum lipids such as ceramides, cholesterol and triacylglycerol using mass spectrometry
Time frame: From enrollment to 12 months of age
Skin microbiome
Overall skin microbiome composition and diversity using next-generation sequencing
Time frame: From enrollment to 12 months of age
Skin metabolites
Levels of skin metabolites using targeted or untargeted approaches.
Time frame: From enrollment to 12 months of age
Immune proteomics
Levels of plasma proteins using mass cytometry or immunoassaysand immunoassays.
Time frame: From enrollment to 6 months of age
Immune blood cell immunophenotyping
Levels of immune cell populations using mass cytometry or immunoassays
Time frame: From enrollment to 6 months of age
Specific IgE antibodies
Specific IgE antibodies will be measured using Phadiatop infant®.
Time frame: At 12 months of age
Fecal microbiome
Overall fecal microbiota composition, diversity, different bacteria taxa and microbiota community types assessed using next generation sequencing (NGS) technology
Time frame: From enrollment to 12 months of age
Fecal metabolites
Levels of fecal metabolites using targeted or untargeted approaches.
Time frame: From enrollment to 12 months of age
Fecal biomarkers of inflammation and immunity
Levels of fecal markers of immune health and inflammation such as total secretory IgA (sIgA), calprotectin, and α-1-antitrypsin assessed by ELISA.
Time frame: From enrollment to 12 months of age
Physician-diagnosed allergic manifestations
Number of participants with Physician-diagnosed allergic manifestations.
Time frame: From enrollment to 12 months of age
Gastrointestinal tolerance
Infant Gastrointestinal Symptom Questionnaire (IGSQ), scores range from 13 to 65, with higher scores indicating higher gastrointestinal discomfort.
Time frame: At enrollment and 4 months of age
Weight
Weight (g and z-scores)
Time frame: From enrollment to 12 months of age
Height
Length (cm and z-scores)
Time frame: From enrollment to 12 months of age
Head circumference
Head circumference (cm and z-scores)
Time frame: From enrollment to 12 months of age
Safety assessment
Incidence of adverse events
Time frame: From enrollment to 13 months of age
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Oct 2027, 30 months after the start.
Of 69 industry-sponsored interventional studies with no phase under Dermatitis, Atopic, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's planned 30 months is above that.
Counting every sponsor, half of 183 studies reached it within 15 months; a quarter within 7 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Société des Produits Nestlé (SPN) →